Surgery and perioperative intralesional corticosteroid injection for treating earlobe keloids: a korean experience by �끂誘몃졊 et al.
Vol. 21, No. 3, 2009 221
Received July 4, 2008, Accepted for publication September 22, 2008
Reprint request to: Kee Yang Chung, M.D., Department of Dermatology, 
Yonsei Medical Center, Yonsei University College of Medicine, 134, 
Sinchon-dong, Seodaemun-gu, Seoul 120-752, Korea. Tel: 82-2-2228- 
2080, Fax: 82-2-393-9157, E-mail: kychung@yuhs.ac
Ann Dermatol Vol. 21, No. 3, 2009
ORIGINAL ARTICLE
Surgery and Perioperative Intralesional Corticosteroid 
Injection for Treating Earlobe Keloids: 
A Korean Experience
Jin Young Jung, M.D., Mi Ryung Roh, M.D., Yeon Sook Kwon, M.D., Kee Yang Chung, M.D., Ph.D.
Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea
Background: The aesthetic implications of ear keloids, 
which affect people of all races, are serious and the treatment 
of earlobe keloids is known to be difficult. The high rate of 
recurrence following excision alone has led to investigating 
various types of adjuvant therapy, including intralesional 
corticosteroid injection. Objective: We evaluated the 
efficacy of excision combined with perioperative intralesio-
nal triamcinolone acetonide injection for treating earlobe 
keloids of Korean patients. Methods: From 1997 to 2006, 
eighteen keloids on the earlobes of fifteen Korean patients 
were treated. The patient age ranged from 15 to 32 years 
(mean age: 24 years). All the patients were female and the 
keloids occurred after ear piercing. Preoperative intrale-
sional triamcinolone acetonide (TA) injection was admini-
stered twice at a 1-month interval. Postoperative intralesio-
nal TA injections were given every 1 month for several 
months, depending on the patient’s clinical progress. 
Results: The follow-up period ranged from 4 to 42 months 
(mean: 18.5 months). After the surgery, TA intralesional 
injections were given 2 to 13 times (mean: 5.2 times). Of the 
treated keloids, eleven showed good results (61.1%) and 
three recurred (16.6%). No complications from the TA 
intralesional injection were observed. Conclusion: Among 
the various treatments for earlobe keloids, we suggest that 
excision with corticosteroid intralesional injection can be 
used as the first line therapy when considering its effect and 
economic advantage. (Ann Dermatol 21(3) 221∼225, 2009)
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INTRODUCTION
Keloids are benign, hard and persistent fibrous proli-
ferations that develop in predisposed persons at sites of 
cutaneous injury1-3. Keloids of the ear usually appear as 
shiny, smooth and globular growths on one or both sides 
of the ear. They are usually preceded by ear piercing, 
trauma or burns1,2. The incidence of keloid formation is 
difficult to assess as it varies from 4.5% to 16% in the 
Black and Hispanic populations4,5. The incidence of 
keloid in dark-skinned people is estimated to be 3 to 20 
times that of light-skinned people1,5-7.
In some cases, nonsurgical therapies such as intralesional 
corticosteroids8, X-ray irradiation9, pressure dressing10, 
silicone gel sheets11, cryotherapy12 and interferon13 were 
reported to be effective to treat keloids. However, even 
though the size of the keloid may decrease with nonsur-
gical treatment alone for the cases of larger lesions, the 
results may not be cosmetically satisfactory. Various sur-
gical methods such as excision followed by primary 
suture14, healing by secondary intention15, skin graft16 or 
local flap17 have been used. Yet surgical excision alone 
has shown varying degrees of success and perioperative 
nonsurgical therapies should be combined to prevent the 
inevitable recurrence after surgical excision.
The purpose of this study was to study the usefulness of a 
combination of surgical excision and perioperative cor-
ticosteroid intralesional injection, which is a very econo-
mical treatment that patients will comply with, for the 
treatment of earlobe keloids in an Asian population.
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Table 1. Patients summary
Case Sex/Age Duration(months) Site Size (cm
2) Previoustreatment
Postoperative
TA ILI
Postoperative
follow-up
(months)
Result
 1 F/28 48 Right 2.5×2.0 -  4 42 G
 2 F/24 12 Left 1.0×0.8 TA ILI  6  8 F
 3 F/24 39 Right 1.0×1.0 -  7 24 F
 4 F/15 24 Right 1.5×1.0 -  9 16 G
 Left 1.5×1.0 -  9 16 G
 5 F/32 48 Left 1.5×1.3 - 13 36 G
 6 F/24 60 Left 1.2×1.0 TA ILI  4  4 R
 7 F/28 36 Right 1.5×1.5 Excision  2 21 G
 8 F/16  8 Right 0.5×1.0 -  6 23 G
 9 F/23 24 Right 0.5×1.0 -  3  6 G
Left 1.0×3.0 -  3  6 G
10 F/24 36 Left 1.0×1.0 TA ILI  6 12 G
11 F/22 12 Left 2.0×1.5 TA ILI  3 28 G
12 F/19 36 Left 0.5×0.8 TA ILI  6 23 F
13 F/23 24 Left 0.5×0.5 TA ILI  3 45 G
14 F/29 11 Right 0.8×0.8 TA ILI  3 40 F
15 F/24 12 Right 0.5×0.5 TA ILI  3 21 R
Left 0.8×1.0 TA ILI  3 21 R
TA ILI: intralesional injection of triamcinolone acetonide, G: no recurrence of keloid and good aesthetic results, F: no recurrence
of keloid and fair aesthetic results, R: recurrence
MATERIALS AND METHODS
Patients
From 1997 to 2006, eighteen earlobe keloids in fifteen 
Korean patients were treated with our protocol. The 
patients’ ages ranged from 15 to 32 years (mean age: 24 
years). All the patients were female and the keloids 
occurred after ear piercing. At the time of treatment the 
lesions have been present from 8 to 60 months (mean: 
28.7 months). Seven patients had keloids on the left ear 
and five patients had keloids on the right ear. Three 
patients had bilateral lesions. The size of the keloids 
ranged from 0.25 to 3 cm2 (mean: 1.25 cm2). Among the 
fifteen patients, eight patients had received prior 
treatments with intralesional corticosteroid injection and 
one patient had received excision (Table 1).
Methods
Preoperative intralesional triamcinolone acetonide (TA) 
injections were administered twice at a 1-month interval. 
A total of 0.1 to 1.0 ml of TA (20∼40 mg/ml) was decided 
upon depending on the size and the activity of the lesions. 
The surgery was performed under local anesthesia with 
using 1% lidocaine and 1：100,000 epinephrine. An 
incision was done within the edge of the keloid. The 
marginal skin of the overlying keloid, which consisted of 
epidermis and the thin dermis overlying the keloid, was 
raised from the fibrous keloid core. The fibrous keloid 
core was completely removed after completely raising the 
marginal skin. After trimming the redundant marginal skin, 
the defects were resurfaced using the marginal skin of the 
overlying keloid. All the wounds were closed with using 
one layer of 6-0 Ethilon without tension. A simple dressing 
was applied after surgery. The postoperative intralesional 
TA injection was started at a 2 week time point after 
surgery and an injection was given every 1 month for 
several months, depending on the patient’s clinical pro-
gress, and a total of 0.1 to 1.0 ml of TA (20∼40 mg/ml) 
was also decided upon depending on the size and the 
activity of the remaining lesions.
The final results were judged during the postoperative 
follow-up period. A good result was defined as a normal- 
appearing, flat scar that needed no further aesthetic 
refinement. A fair result was defined as a flat scar without 
recurrence, but aesthetic refinement was needed. Recur-
rence was defined as any indurated papule or nodule 
extending beyond the borders of the healed scar line of 
the previously excised lesion.
RESULTS
The follow-up period ranged from 4 to 42 months (mean: 
18.5 months). After the surgery, TA intralesional injection 
was performed from 2 to 13 times (mean: 5.2 times).
Among the treated keloids, 11 showed good results (Fig. 
1), 4 showed fair results and 3 recurred (Table 1). We 
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Fig. 1. (A) Patient 4’s earlobe 
keloid before treatment and (B) 6
months after surgery. (C) Patient 
11’s earlobe keloid before treat-
ment and (D) 3 months after 
surgery.
performed dermabrasion on the lesions with fair results. 
For case 6, an earlobe keloid recurred about 4 months 
after the surgery. Preoperative intralesional TA injection 
was administered twice at a 1-month interval and post-
operative intralesional TA injections were done 4 times 
every 1 month. Yet the lesion enlarged during the course 
of performing the postoperative intralesional TA injec-
tions. After the recurrence, the patient did not revisit our 
clinic and we could not provide further treatment for her 
recurred earlobe keloid. For case 15, both earlobe keloids 
recurred about 8 months after surgery. She wanted to be 
transferred to another clinic due to personal reasons and 
we recommended regular intralesional TA injections every 
1 month. For cases 10 and 12, indurated papules on the 
healed scar line occurred 1 month after the surgery. We 
treated the indurated papules with intralesional TA in-
jection twice at a 1-month interval and the indurations 
were resolved. Any adverse effects such as atrophy and 
telangiectasia were not observed at and around the 
injection sites.
DISCUSSION
Keloid development has been associated with different 
types of skin injury, including surgery, ear piercing, 
laceration, burn, vaccination or inflammatory processes1,2. 
With an ever-expanding number of patients undergoing 
body piercing, dermatologists are increasingly being 
consulted for the treatment of ear keloids. Multiple thera-
peutic options are available for the treatment of keloids. 
Combination therapy appears to be the most effective, 
although few previous studies have compared the various 
regimens.
Excision alone of keloids has been associated with recur-
rence rates of 45% to 100%18,19. Numerous treatments 
after excision have been used such as postexcisional 
injections of corticosteroids8 or interferon13, radiothe-
rapy9, pressure splints10 and silicone sheeting11. In a large 
review of the literature, Friedman20 proposed surgical 
excision and corticosteroids for small keloids, pressure 
therapy and a combination of surgery and steroid for 
moderately large scars and a combination of surgery and 
postoperative radiotherapy for very large, resistant scars. 
Earlier studies have shown that postexcisional TA injection 
is associated with a recurrence rate of 0% to 100%, but 
the majority of studies reported less than a 50% re-
currence rate18. The recurrence rate in our study was 
16.6%.
Berman and Flores13 reported a recurrence rate of 18.7% 
when interferon alpha-2b injections were given after 
keloid excisions. Their result was lower than the re-
currence rate achieved with excision alone (51%) or a 
combination of excision and postoperative triamcinolone 
intralesional injection (58%). Although the recurrence rate 
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Table 2. Keloid treatment using surgery and intralesional TA injection in the literature
Study (year) Number Age (years) Site Follow-up (months)  Recurrence (%)
Singleton and Gross25 (1971) 54 19.8 (12∼58) Ear 12  4 (7%)
Kiil26 (1977) 15     - Whole body 24∼60 13 (86.7%)
Barton27 (1978) 19     - Ear  6∼48  0 (0%)
Shons and Press8 (1983) 31　 18 (13∼19) Ear 35 (12∼62)  1 (3%)
Salasche and Grabski28 (1983)  6 18.3 (16∼22) Ear ＞12  0 (0%)
Sclafani et al.23 (1996) 12     - Ear 19  4 (33.3%)
Berman and Flores13 (1997) 65     - Whole body  7.5 38 (58.5%)
Our study (2007) 18 24 (15∼32) Ear 28.7 (4∼42)  3 (16.6%)
of interferon injection after excision is known to be low, 
interferon treatment is more expensive than TA intra-
lesional injection and the results are similar to ours. 
Recurrence rates of as low as 2%, but up to 50%, have 
been reported following postoperative external-beam 
radiotherapy21,22. A randomized controlled trial of earlobe 
keloid excision followed by either intralesional steroid 
injection or radiotherapy has shown that radiotherapy has 
a lower recurrence rate than that of steroid injection, a 
statistically significant difference was not observed23. 
Although surgical excision combined with radiotherapy 
has shown fairly successful results in treating resistant 
keloids, many surgeons are still reluctant to use ionizing 
radiation for the treatment of benign diseases.
Surgery followed by pressure treatment has shown a good 
response rate of 90∼100%, and especially after excision 
of earlobe keloids10. However, the pressure must be 
maintained day and night for a minimum of 6∼9 months, 
and premature release is frequently followed by recur-
rence of the lesion.
Topical silicone sheets have been shown to soften scars 
and reduce itching, and children like this treatment 
because the gel-sheeting is painless. It usually takes 6∼12 
months of therapy to achieve the best results, but most 
patients become noncompliant after several months 
because of the treatment’s duration and the inconvenience 
of cutting and placing the silicone gel-sheeting on the 
keloid11.
The postsurgical use of imiquimod 5% cream has re-
cently been reported24. All 4 patients were successfully 
treated without recurrence for 12 months after their final 
excision. Although imiquimod 5% cream following 
tangential shave excision was effective, most patients 
experienced mild to marked irritation secondary to the 
daily application. Those with marked irritation will some-
times have to discontinue the medication for several days 
to a week. The patients who have large surgical sites and 
wounds closed with flaps, grafts or tension should not start 
imiquimod cream therapy for four to six weeks post-
operatively because early application often causes the 
surgical site to splay or dehisce.
The use of steroid injections as an adjunctive procedure 
after keloid excision had been reported with using various 
dosages, schedules and concentrations of drug. When 
excision was combined with postoperative intralesional 
triamcinolone acetonide injection, the recurrence rates 
were 0∼86.7% (Table 2)8,13,23,25-28. Table 2 showed that 
the recurrence rates (0∼33.3%) for the ear keloids were 
lower than those for keloids other sites and our study 
showed a 16.6% recurrence rate. Shons and Press8 
reported that only 3% of earlobe keloids recurred after 
excision and three injections of 40 mg/ml triamcinolone at 
a 4 week interval and beginning 3 weeks postoperatively. 
Singleton and Gross25 reported on the treatment of auri-
cular and lobular keloids using a posterior approach for 
excision followed by steroid injection at immediately 
postoperative period. Steroid injections were then con-
tinued at a 1-month interval postoperatively for 1 year. For 
the 21 patients who were followed for more than one 
year, there were 13 good results and 2 recurrences. For 
the 33 patients who were followed for less than one year, 
24 showed good results and 2 recurred. The corticosteroid 
inhibits alpha2-macroglobulin, which in turn inhibits 
collagenase. Once this pathway is blocked, collagenase is 
elaborated, thus enabling collagen degeneration29. 
The risk of relapse following these treatments depends on 
local wound-related factors and general patient-related 
factors. A high recurrence rate is seen at sites where have 
keloids developed after tensioned wound closure, wound 
infection and dehiscence. Patients with a positive family 
history and a past history of recalcitrant keloids with prior 
treatment failures are at a greater risk of recurrence30.
The high rate of recurrence following excision alone has 
led to the investigation of many different types of adjuvant 
therapy, but of these techniques has been demonstrated to 
be optimal. Until one strategy is shown to be clearly 
superior, the choice of adjuvant treatment needs to be 
tailored to the individual patient and the clinical situation. 
Although various treatments after surgery have previously 
been used, we think that excision with corticosteroid 
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intralesional injections can be used as the standard treat-
ment for earlobe keloids.
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